ArticleBMC plant biology2026
Variation in phytochemical profiles and anti-cholinesterase activity across wild Iranian populations of Leucojum aestivum L.: a conservation perspective.
Article in BMC plant biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeucojum aestivum L. (Amaryllidaceae) is a perennial bulbous species of high pharmaceutical importance, primarily recognized as a natural source of the alkaloid galantamine for Alzheimer’s disease treatment. Iranian L. aestivum populations (LAPs) may contain unique alkaloids with strong acetylcholinesterase (AChE) inhibitory effects, making them a conservation priority. To investigate phytochemical diversity and bioactivity, eight natural populations including LAP1 (Chahar Deh, Astaneh Ashrafieh); LAP2 (Baz Kia Gurab, Lahijan); LAP3 (Sangar); LAP4 (Chomesghal, Ziabar); LAP5 (Pinchah, Astaneh Ashrafieh); LAP6 (Chaboksar); LAP7 (Valiseh, Rudsar); and LAP8 (Vali Abad, Tonkabon) were sampled during the flowering stage. Galantamine, lycorine, total phenolic content (TPC), total flavonoid content (TFC), antioxidant capacity (FRAP and DPPH), and AChE inhibitory activity were quantified in bulbs and leaves.
resultsThe highest AChE inhibition was recorded in bulbs of LAP6 (IC50: 95.57 µg/ml) and LAP7 (IC50: 102.38 µg/ml), corresponding to elevated galantamine levels (20.31 and 24.92 mg/g dry extract, respectively), which showed a strong positive correlation (r = 0.880, p < 0.01). In contrast, LAP8 contained no detectable galantamine in bulbs but exhibited exceptionally high leaf lycorine content (107.91 mg galanthamine equivalent/g dry extract) and antioxidant capacity (FRAP: 90.71 µmol Fe²⁺/g DW; DPPH, IC₅₀: 95.10 µg/ml), alongside moderate AChE inhibition (IC50: 150.80 µg/ml in bulbs, 231.63 µg/ml in leaves). Leaf TPC (8.57–13.39 mg GAE/g DW) consistently exceeded bulb TPC (0.18–7.59 mg GAE/g DW). Cluster analysis grouped populations into three distinct classes: balanced alkaloid levels and antioxidant power (LAP1, LAP5, LAP6), lower alkaloid levels (LAP2, LAP3, LAP4), and high phenolic content and antioxidant power with relatively elevated alkaloid levels (LAP7, LAP8).
conclusionsThese findings demonstrated a strong linkage between alkaloid composition and bioactivity, highlighting the pharmaceutical potential of specific chemotypes and emphasizing the necessity of in situ conservation and ex situ cultivation for sustainable utilization and drug development targeting cholinesterase inhibition and antioxidant activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.